LSE •
Healthcare •
Biotechnology •
Quote as of 06/05/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeLSE
Market Capitalization6.51 mln
Float23.13 mln
Earnings Date06/12/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-1.47
Manipulation likely
Relative Strength
84
/ 100
Strongly outperforming
Debt / Equity
0.00
Debt-free
ROE
-94.17
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
CRISM Therapeutics Corporation is a medical company focused on improving how chemotherapy reaches solid tumors by delivering treatment directly into cancer tissue rather than through the bloodstream. Its primary product, ChemoSeed, is a small biodegradable implant placed directly at the tumor site, designed to release chemotherapy drugs locally and more effectively. The company also supports other organizations through drug formulation and advisory services. Founded in 2016 and headquartered in Road Town, British Virgin Islands, CRISM was previously known as Amur Minerals Corporation before adopting its current name in May 2024.
